

Appl. No. : 09/380,534
Filed : September 1, 1999

21. (Amended) [A] The method according to Claim 20, wherein the cytokine is GM-CSF, IL-12, IL-2, TNF, IFN γ , IL-18, IL-3, IL-4, IL-8, IL-9, IL-13, IL-10, IL-14, IL-15, G-SCF, IFN alpha, IFN beta, IFN gamma, TGF alpha, TGF beta.

Kindly add new claims 39 through 60 as follows:

39. (New) The method of claim 1, wherein said antigen is provided as a polypeptide.

40. (New) The method of claim 39, wherein the polypeptide consists of about 8-10 amino acids.

41. (New) The method of claim 39, wherein the polypeptide is derived from a tumor-associated antigen.

42. (New) The method of claim 41, wherein said tumor-associated antigen is selected from the group consisting of MART-1/MelanA (MART-1), gp100 (Pmel 17), tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15(58), CEA p53, Ras, HER-2/neu, BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, EBVA, (HPV) antigens E6 and E7, TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, H-ras, β -Catenin, CDK4, Mum-1, p15, p16.

43. (New) The method of claim 39, wherein the polypeptide is derived from a microbial antigen.

44. (New) The method of claim 1 wherein said antigen is provided as a component of a microorganism.

45. (New) The method of claim 44 wherein said microorganism is a protozoan.

46. (New) The method of claim 44 wherein said microorganism is a bacterium.

47. (New) The method of claim 44 wherein said microorganism is a virus.

48. (New) The method of claim 1, wherein said antigen is provided a nucleic acid encoding the antigen.

49. (New) The method of claim 48, wherein the nucleic acid comprises a plasmid.

50. (New) The method of claim 49, wherein the expression vector further comprises a bacterium.

51. (New) The method of claim 48, wherein the expression vector comprises a virus.

Appl. No. : 09/380,534
 Filed : September 1, 1999

52. (New) The method of claim 51, wherein the virus is selected from the group consisting of vaccinia virus, adenovirus, adeno-associated virus, retroviruses, and herpesviruses.

53. (New) The method of claim 48, wherein said nucleic acid encodes a tumor-associated antigen.

54. (New) The method of claim 53, wherein said tumor-associated antigen is selected from the group consisting of MART-1/MelanA (MART-1), gp100 (Pmel 17), tyrosinase, TRP-1, TRP-2, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, p15(58), CEA p53, Ras, HER-2/neu, BCR-ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR, EBVA, (HPV) antigens E6 and E7, TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY-ESO, p185erbB2, p180erbB-3, c-met, nm-23H1, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1, NuMa, K-ras, H-ras, β -Catenin, CDK4, Mum-1, p15, p16.

55. (New) The method of Claim 48, wherein said nucleic acid encodes a microbial antigen.

56. (New) The method of Claim 55, wherein said antigen is a viral antigen.

57. (New) The method of Claim 55, wherein said antigen is a bacterial antigen.

58. (New) The method of Claim 55, wherein said antigen is a protozoal antigen.

59. (New) The method of claim 48, wherein said antigen is provided as a polypeptide.

60. (New) The method of claim 59, wherein said antigen consists of about 8-10 amino acids.

COMMENTS

Claims 19-21 have been amended to correct typographical errors. New Claims 39-60 have been added. Support for new claims 39-40 and 55-60 is found at page 20, lines 9-24. Support for new claims 41 and 53 is found at page 53, lines 1-2. Support for new claims 42 and 54 is found in claims 19 and 29 as originally filed and at page 21, lines 19-30. Support for new claims 43-44 is found at page 20, line 24 to page 22 line 6 and Tables I-III on pages 23-52. Support for new claims 45-47 is found at page 15, line 14 and page 17, lines 29-31. Support for new claims 48-51 and 55-58 is found at page 53, lines 11-17. Support for new claim 52 is found in Tables I-III, on pages 23-52. No other changes have been made in this Preliminary Amendment, and no new matter has been added.

Appl. No. : 09/380,534
Filed : September 1, 1999

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 13 Nov 2000

By: 

Dale C. Hunt
Registration No. 41,857
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(619) 235-8550

S:\DOCS\MTM\MTM-1039.DOC:gem
110300